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The large intestine contains five types of endocrine cells that regulate its functions by sensing its luminal contents and releasing
specific hormones. Chromogranin A (CgA) is a common marker for the gastrointestinal endocrine cells, and it is abnormal in
irritable bowel syndrome (IBS) patients. Most IBS patients relate their symptoms to certain food elements. The present study
investigated the effect of dietary guidance on the total endocrine cells of the large intestine as detected by CgA in 13 IBS
patients.Thirteen control subjects were also included. Each patient received three sessions of dietary guidance. Colonoscopies were
performed on controls and patients (at baseline and at 3–9 months after receiving guidance). Biopsy samples from the colon and
rectum were immunostained for CgA and quantified by computerized image analysis. The densities of CgA cells in the total colon
(mean ± SEM) among the controls and the IBS patients before and after receiving dietary guidance were 83.3 ± 10.1, 38.6 ± 3.7, and
64.7 ± 4.2 cells/mm2, respectively (𝑃 = 0.0004), and were unchanged in the rectum. In conclusion, the increase in CgA cell density
after receiving dietary guidance may reflect a change in the densities of the large intestinal endocrine cells causing an improvement
in the IBS symptoms.
1. Introduction
Irritable bowel syndrome (IBS) is a common gastrointestinal
(GI) disorder that is present in almost one-third of con-
sultations with gastroenterologists [1, 2]. IBS predominates
among females, and its reported prevalenceworldwide ranges
from 5% to 20% [1–6]. The symptoms of IBS vary from mild
to severe and are attributed to visceral hypersensitivity, dis-
turbedGImotility, or abnormal GI secretion [7–9]. Gastroin-
testinal sensation, motility, and secretion are regulated by the
neuroendocrine systemof theGI tract [7, 8], which comprises
the GI endocrine cells and the enteric nervous system [1, 10].
The GI endocrine cells comprise almost 1% of all epithelial
cells in the GI tract and are considered the largest endocrine
organ in the body [11–13]. These cells project specialized
microvilli into the lumen, which sense its contents (mainly
nutrients) and release specific hormones into the lamina pro-
pria [14–26]. The large intestines, namely, the colon and rec-
tum, contain five types of endocrine cell: serotonin-, peptide-
YY-, somatostatin-, oxyntomodulin- (enteroglucagon-), and
pancreatic-polypeptide-producing cells [27–29].
Chromogranin A (CgA) is considered to be a common
marker for the GI endocrine cells [30–32]. The CgA cell
density was previously found to be abnormal in the colon
of patients with IBS [33] but not in the rectum [27]. Such
abnormalities in the gastrointestinal cells in IBS patients,
involving not only the large intestines but also the gastric
mucosa, have been suggested to play a major role in the
pathophysiology of IBS [7, 34–36].
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Most patients with IBS relate their symptomdevelopment
to the consumption of certain food elements [37, 38]. Dietary
management achieved by providing individualized guidance
has been reported to improve the symptoms and quality
of life of IBS patients [39, 40]. The same dietary guidance
normalizes the gastric endocrine cells [41, 42], and thus the
present study investigated whether dietary guidance affects
the total endocrine cells of the large intestine as detected by
CgA.
2. Material and Methods
2.1. Patients and Controls. Patients referred to the Gastroen-
terology Division, Stord Hospital, Norway, who were aged
18–70 years and had IBS according to the Rome-III criteria,
were recruited for this study. Women who were pregnant or
lactating or who received a caesarean section or hysterectomy
and patients who had organic gastrointestinal or any other
systemic diseases, abused drugs, or suffered from serious
psychiatric illness were excluded. Patients with previous
abdominal surgery, with the exception of appendectomy,
were also excluded.
Seven patients did not use medications prior to the
study, while six patients consumed one or a combination of
several medications. Four patients consumed proton pump
inhibitors (PPI), one used an antihypertensive angiotensin
II receptor antagonist, three used medications against aller-
gies, two consumed contraceptive pills, two took thyroxin
substitution tablets, one used inhalator against asthma, and
two used antidepressants/anxiolytics. These patients were
informed not to take any kind of PPI during the study.
Patients with gastrointestinal bleeding, where the source
of bleeding was identified as hemorrhoids (𝑛 = 3) or
angiodysplasia (𝑛 = 1), or healthy subjects who underwent
a colonoscopy due to health worries caused by family mem-
ber(s) having been diagnosed with gastrointestinal cancer
(𝑛 = 9) were used as controls. The control group consisted
of nine females and four males with a mean age of 54 years
(range 26–70 years).
The study was approved by the local Committee for
Medical Research Ethics West, Bergen, Norway, and was
performed in accordance with the Declaration of Helsinki.
The patients provided both oral and written consent to
participate.
2.2. Study Design. A total of 46 patients were included in
the study, comprising 35 females and 11 males with a mean
age of 35 years (range 18–69 years). All of the patients were
examined physically and had their blood tested in order to
exclude the presence of inflammation, infection, and other
organic diseases. Segmental biopsy samples were taken dur-
ing the colonoscopies in order to exclude microscopic colitis.
All of the patients received three sessions of individualized
dietary guidance lasting about 45min each. The sessions
were scheduled at intervals of at least 2 weeks and were
conducted by a nurse experienced in dietary guidance in IBS.
Thepatients underwent colonoscopies, before the first dietary
guidance session and at 3–9 months (median 4 months) after
the third session.
2.3. Individualized Dietary Guidance. The information about
IBS and dietary guidance was delivered both orally with the
help of charts and as written illustrated information. During
the first session, the patients received general information
about IBS, the importance of regular and healthy eating
habits, and the food elements that trigger IBS symptoms, that
is, insoluble dietary fiber and poorly absorbed FODMAPs
(fermentable oligosaccharides, disaccharides, monosaccha-
rides, and polyols). The daily consumption of dairy prod-
ucts was allowed during the study, with the patients being
informed that lactose-free milk and lactose-free dairy prod-
ucts do not provoke IBS symptoms. The patients were asked
to test a fat-, protein-, or carbohydrate-rich/poor diet for
2 weeks. During this period the patients were instructed
to register in a diary their daily intake of food and fluids
along with any symptoms they experienced including the
frequency and degree of abdominal pain, abdominal dis-
tension, and stool frequency and consistency. Consuming
food items supplemented with probiotics, antibiotics, and
other medications was not permitted during the course of
the study unless otherwise specified. In the second session,
the nurse briefly repeated the information given at the first
session and together with the patient identified the symptom-
triggering food elements based on an assessment of the
patient’s diary. The patients were then encouraged to change
the proportions of protein, fat, and carbohydrate in their diet,
avoid FODMAPs-rich items and insoluble fiber, and consume
vegetables and fruits with lower amounts of FODMAPs and
insoluble fiber. During the third session, the patients shared
their experiences concerning the dietary guidance with the
nurse. The nurse together with the patient then designed
a suitable diet for the patient to strictly follow until the
endpoint of the study.
2.4. Dietary Assessment. Dietary intake was assessed by
using MoBa food frequency questionnaire (MoBa FFQ).
This questionnaire is semiquantitative and self-administered
and reports the frequency and meal size related to a series
of foods and beverages consumed over a defined period
of time. The data were then analyzed using software to
calculate the nutrient content of the diet. TheMoBa FFQ was
developed and validated by the Norwegian Institute of Public
Health in Oslo, Norway [43, 44]. This questionnaire inquires
about the consumption of 225 food items and identifies the
respondent’s dietary habits, including the consumption of
oral supplements (if any), according to typical Norwegian
meal patterns. The participants completed the MoBa FFQ
form before the first session and again at least 3 months after
the last session of dietary guidance [39].
2.5. Colonoscopies, Tissue Sampling, Histopathology, and
Immunohistochemistry. Colonoscopies were performed on
both patients and controls. Biopsy samples were taken from
the right colon (the cecum, the ascending colon, and the
right half of the transverse colon), the left colon (the left
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half of the transverse colon, the descending colon, and the
sigmoid colon), and the rectum about 15 cm from the anus.
Four biopsies were taken from each segment.
The biopsy samples were fixed overnight in 4% buffered
paraformaldehyde, embedded in paraffin wax, and then cut
into 5 𝜇m thick sections. The sections were stained with
hematoxylin-eosin and immunostained using the method
involving the Avidin-Biotin complex (ABC) with the Vectas-
tain ABC kit (Vector Laboratories, Burlingame, CA, USA)
and the chromogen 3,3󸀠-diaminobenzidine peroxidase sub-
strate (DAB) kit (Vector Laboratories) as described in detail
previously [27]. Briefly, after 2 hours of incubation with a
monoclonal mouse anti-N-terminal of purified CgA primary
antibody (code number M869; Dako, Glostrup, Denmark)
diluted to 1 : 1000, at room temperature, the sections were
washed in phosphate-buffered-saline (PBS; pH 7.4) and incu-
bated for another 30min at room temperature with biotiny-
lated swine anti-mouse IgG (diluted to 1 : 200).The antibodies
were raised to N-terminal of purified chromogranin A.These
antibodies reacted with human chromogranin A as validated
earlier [33].The slides were then washed with PBS, incubated
for a further 30min with ABC (diluted to 1 : 100), and
then submerged in DAB, followed by counterstaining with
hematoxylin.
2.6. Computerized Image Analysis. The densities of CgA in
the right colon, left colon, and rectum of patients with IBS
and controls were evaluated using computer software (Cell
∧D, Olympus, Tokyo, Japan) under a ×40 objective. The
number of CgA positive cells and the area of the epithelial
cells were measured in ten randomly chosen fields. Each field
represented a tissue area of 0.14mm2. The CgA cell density is
expressed herein as the number of cells per square millimetre
of epithelium. All of the slides were quantified by the same
person (Tarek Mazzawi) who was unaware of the identity of
the sections.
2.7. Statistical Analysis. Thepaired t-test was used to compare
patients before and after receiving dietary guidance and the
unpaired t-test was used to compare between themale and the
female patients before and after receiving dietary guidance.
The data are presented as mean ± SEM values. 𝑃 values < 0.05
were considered indicative of statistical significance.
3. Results
3.1. Patients and Controls. Of the 46 patients recruited in the
study, 24 lost theirmotivation to continue participating in the
study and withdrew their consent due to symptom improve-
ment as a consequence of receiving dietary guidance and/or
being unwilling for a second colonoscopy to be performed.
Two patients were excluded because of noncompliance, two
were diagnosed with celiac disease, one was diagnosed
with lupus, and one received antibiotic treatment because
of gastroenteritis. A further three patients were excluded
because they became pregnant during the study and moved
abroad, or technical difficulties were experienced during the
colonoscopy. Thus, 13 of the original 46 patients completed
the entire study; these patients comprised 8 females and 5
males with a mean age of 34 years (range 20–45 years).
3.2. Colonoscopies, Histopathology, and Immunohistochemis-
try. The colon and rectumwere macroscopically normal and
the histopathological examinations revealed normal struc-
tures in both patients and controls. CgA-immunoreactive
cells were found in the mucosa of both the colon and rectum
of the patients and controls. These cells were either basket-
or flask-shaped and sometimes had a long basal cytoplasmic
process.
3.3. Dietary Assessment. The effect of dietary guidance
has been described in detail elsewhere [39]. In brief, the
patients had a significantly lower daily total consumption of
FODMAPs-rich fruits and vegetables after receiving dietary
guidance (9.2 ± 3.2 g) than before receiving dietary guidance
(16.2 ± 5.3 g, 𝑃 = 0.016). On the other hand, the daily
consumption of dietary fiber did not differ significantly
between before (27.4 ± 2.5 g) and after (23.1 ± 2.2 g) receiving
dietary guidance (𝑃 = 0.093).
3.4. Computerized Image Analyses
3.4.1. Colon. In the control group, the densities of CgA cells
in the total colon, right colon, and left colon were 83.3 ± 10.1,
33.7 ± 5.3, and 49.6 ± 6.0 cells/mm2, respectively.
The densities of CgA cells in the total colon of IBS
patients were 38.6 ± 3.7 and 64.7 ± 4.2 cells/mm2 before and
after receiving dietary guidance, respectively; this increase
was statistically significant (𝑃 = 0.0004) (Figures 1(a) and
2). The densities of CgA cells before and after receiving
dietary guidance were 16.7 ± 1.9 and 24.4 ± 2.1 cells/mm2,
respectively, in the right colon, and 21.9 ± 2.7 and 40.3 ±
3.6 cells/mm2 in the left colon. The increases in CgA cell
densities in both the right colon (Figure 1(b)) and left colon
(Figure 1(c)) were statistically significant (𝑃 = 0.0157 and
0.0039, resp.). By comparing CgA cell densities between
males and females, no statistically significant difference was
found before and after receiving dietary guidance (Table 1).
3.4.2. Rectum. The densities of the CgA cells in the rectum
were 49.0 ± 7.9, 42.7 ± 6.5, and 47.6 ± 5.0 cells/mm2 in the
controls and in the IBS patients before and after receiving
dietary guidance, respectively (Figures 3 and 4). The cell
density in the rectum did not differ significantly between
before and after receiving dietary guidance in the IBS patients
(𝑃 = 0.47). In addition, no significant difference was found in
CgA cell density between males and females before and after
receiving dietary guidance (Table 1).
4. Discussion
The dropout rate of patients with IBS is reportedly high in
clinical studies, ranging between 33% and 48% [40, 45–48].
The current study included two colonoscopies and needed
the patients to follow a strict diet for at least 3 months.
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Figure 1: CgA cell densities in the total colon (a), right colon (b), and left colon (c) of IBS patients before and after receiving dietary guidance.
The dashed lines labeled “a” and “c” indicate the upper and lower limits of the 95% confidence interval for control subjects, respectively, while
line “b” indicates the mean CgA cell density. ∗𝑃 < 0.05. ∗∗𝑃 < 0.001. ∗∗∗𝑃 < 0.0001.
Table 1: Densities of chromogranin A cells in the total colon, right colon, left colon, and rectum of the patients, defined by their gender,
before and after receiving dietary guidance.
Location
Endocrine cell densities (cells/mm2)
𝑃 values before
guidance
𝑃 values after
guidanceMales before
guidance
Females before
guidance
Males after
guidance
Females after
guidance
Total colon 37.8 41.1 68.6 65.9 0.7 0.8
Right colon 18.2 17 21.4 28.1 0.8 0.1
Left colon 19.6 23.4 47.2 36 0.5 0.1
Rectum 53.8 36.6 55.8 43.1 0.2 0.2
This demanding design may have contributed to the even
higher dropout rate of 52%. Most of these dropouts were due
to improvements in the patients’ symptoms after receiving
dietary guidance. Additional factors further increased the
dropout rate to 72%, such as exclusion after being diagnosed
with celiac disease, lupus, pregnancy, moving abroad, and
technical difficulties experienced during the colonoscopy.
CgA is a member of the granin (chromogranin-
secretogranin) family located within the vesicles of neurons
and endocrine cells [30, 31, 49], and it serves as a marker
for the GI endocrine cells, endocrine tumors, and gut
inflammation [30–33]. A significant change in the densities
of the endocrine cells of the colon occurred following
changes in the diet in the IBS patients, with the values
moving towards those measured for the control subjects.
The density of CgA cells in the colon was abnormal in
IBS patients before receiving dietary guidance, which is
in line with a previous report [33]. However, the density
of CgA cells in the rectum of IBS patients did not differ
from the control subjects, which was in line with what was
reported previously [27]. Such findings were attributed to
the physiological functions differing between the colon and
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Figure 2: CgA-immunoreactive cells in the total colon of a control subject (a) and of an IBS patient before (b) and after (c) receiving dietary
guidance.
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Figure 3: CgA cell density in the rectum of IBS patients before and
after receiving dietary guidance. The symbols are the same as in
Figure 1.
rectum, in that the colon absorbs water, sodium, and some
fat-soluble vitamins, whereas the rectum’s sole role is as a
reservoir for the feces prior to defecation [27].
There are contradictory results concerning the blood lev-
els of CgA in IBS. Some results show low levels of serumCgA
[50], and others show higher levels of CgA [51] or unchanged
levels in IBS patients [33]. As CgA-immunoreactive cells
occur in all the segments of the GI tract, the different
serum levels reflected segments other than large intestine or
stomach.
As described previously, the main triggers of the GI
endocrine cells are the luminal contents of the GI tract,
especially the nutrients [7, 36]. The turnover from stem
cells to mature endocrine cells is rapid [52, 53]. It can be
speculated that changing the pattern of food intake—with
the subsequent improvement in IBS symptoms—can alter the
differentiation of the endocrine cells and explain the observed
increase in the CgA cell density in both the colon and rectum
towards the values measured for the control subjects. The
interaction between food type and food intake is a dynamic
process [54].
The CgA cell densities in the colon and the rectum did
not differ betweenmales and females before receiving dietary
guidance, which is in line with previous results [28], nor was
there any difference in the cell densities after receiving dietary
guidance, as shown in Table 1.
A previous study has shown that the density of CgA cells
is abnormal in IBS patients and was reduced in the colon
indicating a reduction in the density of total endocrine cells
[27]. These cells interact with intraluminal nutrients in the
gut and release different hormones accordingly and control
the functions of the GI tract. Since the symptoms of most
IBS patients developed after consuming certain foods, one
could speculate that there might be a relationship between
diet and the GI endocrine cells. The findings of the present
6 Gastroenterology Research and Practice
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Figure 4: CgA-immunoreactive cells in the rectum of a control subject (a) and of an IBS patient before (b) and after (c) receiving dietary
guidance.
study show that the GI endocrine cells may be involved in the
pathophysiology of IBS and symptom development and that
dietary guidance is an important key factor in managing and
improving IBS symptoms. After receiving dietary guidance
the densities of these cells normalize as well as the IBS
symptoms, which indicates that these cells play a role in
the pathogenesis of IBS, providing that they were abnormal
under symptom development and normal again when the
symptoms improved. The change in the CgA cell density
after receiving dietary guidance may reflect a change in the
densities of the large intestinal endocrine cells. Future studies
should attempt to determine which endocrine cell type(s) is
(are) affected.
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